Skip to main content
. Author manuscript; available in PMC: 2013 May 19.
Published in final edited form as: AIDS. 2011 Sep 10;25(14):1779–1787. doi: 10.1097/QAD.0b013e328349f067

Figure 2. ICER of Testing for & Treating Acute HIV Infection by HIV Prevalence.

Figure 2

The horizontal axis displays the initial HIV prevalence in the total modeled population, and the vertical axis shows the incremental cost-effectiveness ratio (ICER) relative to the status quo. Under each strategy, 50% of individuals identified as acutely infected receive antiretroviral therapy (ART) for the duration of their acute infection. Incremental costs and quality-adjusted life years (QALYs) used to calculate the ICER are calculated over a 20-year time horizon and are discounted to the present at 3% annually.

Note: Ab = antibody, VL = viral load, Symptom-based = 35% of symptomatic acutely infected MSM receive Ab & VL testing.